학술논문
华蟾素对晚期肺癌患者凝血状态、治疗效果和生活质量的影响 / Effect of cinobufagin capsule on coagulation state, therapeutic effect and quality of life in patients with advanced lung cancer
Document Type
Academic Journal
Author
Source
中国基层医药 / Chinese Journal of Primary Medicine and Pharmacy. 26(14):1679-1682
Subject
Language
Chinese
ISSN
1008-6706
Abstract
目的 探讨华蟾素胶囊对晚期肺癌患者凝血状态、治疗效果和生活质量的影响.方法 选取晋中市第二人民医院2017年2月至2018年1月收治的晚期肺癌患者64例,采用随机数字表法分为对照组、观察组各32例,对照组采用化疗,观察组采用华蟾素胶囊联合化疗.观察两组治疗前后凝血状态、生活质量评分、疼痛数字(NRS)评分、功能状态(KPS)评分,比较两组临床疗效.结果 治疗前,两组血浆纤维蛋白原(FIB)、血小板(PLT)、D-二聚体、生活质量评分、NRS评分、KPS评分差异均无统计学意义(均P>0.05).治疗后,观察组FIB、PLI、D-二聚体分别为(3.6 ± 0.9)g/L、(248.3 ± 11.3) ×109/L、(19.8 ± 1.2)mg/L,均显著低于对照组的(4.5 ± 0.6)g/L、(398.2 ± 16.2) ×109/L、(40.2 ± 0.6) mg/L(t=11.642、21.045、18.249,均P＜0.05);观察组总有效率为90.6%(29/32),显著高于对照组的68.8%(22/32)(χ2 =6.903,P＜0.05);两组生活质量评分均改善,且观察组生活质量评分均显著高于对照组( t=11.642、21.045、18.249、17.218,均P＜0.05);观察组NRS评分(3.62 ± 1.53)分,显著低于对照组的(5.01 ± 2.34)分,KPS评分(78.25 ± 3.81)分,显著高于对照组的(72.34 ± 4.12)分,差异均有统计学意义(t=16.082、15.082,均P＜0.05).结论 华蟾素胶囊联合化疗治疗晚期肺癌有显著疗效,可明显改善患者凝血状态、提高患者生活质量.
Objective To explore the effects of cinobufagin capsule on coagulation status,therapeutic effect and quality of life of patients with advanced lung cancer.Methods A total of 64 patients with advanced lung cancer admitted to the Second People＇s Hospital of Jinzhong from February 2017 to January 2018 were selected,and they were divided into control group and observation group by random number table method,with 32 cases in each group.The control group was treated with chemotherapy, and the observation group was treated with cinobufagin capsules combined with chemotherapy.Blood coagulation status,quality of life score,pain numerical rating scale ( NRS) and functional status score( KPS) were observed before and after treatment in the two groups.The clinical efficacy was compared between the two groups. Results Before treatment, there were no statistically significant differences in plasma fibrinogen(FIB),platelet(PLT),D-dimer,quality of life score,NRS score and KPS score between the two groups(all P>0.05).After treatment,the FIB,PLI and D-dimers in the observation group were (3.6 ± 0.9)g/L, (248.3 ± 11.3) ×109/L,(19.8 ± 1.2) mg/L respectively,which were significantly lower than those in the control group [(4.5 ± 0.6)g/L,(398.2 ± 16.2) ×109/L,(40.2 ± 0.6) mg/L] (t=11.642,21.045,18.249,all P＜0.05).The total effective rate of the observation group was 90.6%(29/32),which was significantly higher than 68.8%(22/32) of the control group ( χ2 =6.903,P ＜0.05). The quality of life scores of the two groups were improved,and the life scores of the observation group were significantly higher than those of the control group( t=11.642,21.045,18.249,17.218,all P＜0.05).The NRS score of the observation group (3.62 ± 1.53) points was significantly lower than that of the control group[(5.01 ± 2.34)points],and the KPS score of the observation group [(78.25 ± 3.81) points] was significantly higher than that of the control group [( 72. 34 ± 4. 12 ) points], the differences were statistically significant (t =16.082,15.082,all P ＜0.05). Conclusion Treatment of advanced lung cancer with cinobufagin capsule combined with chemotherapy can significantly improve the coagulation state, treatment effect and quality of life of patients.
Objective To explore the effects of cinobufagin capsule on coagulation status,therapeutic effect and quality of life of patients with advanced lung cancer.Methods A total of 64 patients with advanced lung cancer admitted to the Second People＇s Hospital of Jinzhong from February 2017 to January 2018 were selected,and they were divided into control group and observation group by random number table method,with 32 cases in each group.The control group was treated with chemotherapy, and the observation group was treated with cinobufagin capsules combined with chemotherapy.Blood coagulation status,quality of life score,pain numerical rating scale ( NRS) and functional status score( KPS) were observed before and after treatment in the two groups.The clinical efficacy was compared between the two groups. Results Before treatment, there were no statistically significant differences in plasma fibrinogen(FIB),platelet(PLT),D-dimer,quality of life score,NRS score and KPS score between the two groups(all P>0.05).After treatment,the FIB,PLI and D-dimers in the observation group were (3.6 ± 0.9)g/L, (248.3 ± 11.3) ×109/L,(19.8 ± 1.2) mg/L respectively,which were significantly lower than those in the control group [(4.5 ± 0.6)g/L,(398.2 ± 16.2) ×109/L,(40.2 ± 0.6) mg/L] (t=11.642,21.045,18.249,all P＜0.05).The total effective rate of the observation group was 90.6%(29/32),which was significantly higher than 68.8%(22/32) of the control group ( χ2 =6.903,P ＜0.05). The quality of life scores of the two groups were improved,and the life scores of the observation group were significantly higher than those of the control group( t=11.642,21.045,18.249,17.218,all P＜0.05).The NRS score of the observation group (3.62 ± 1.53) points was significantly lower than that of the control group[(5.01 ± 2.34)points],and the KPS score of the observation group [(78.25 ± 3.81) points] was significantly higher than that of the control group [( 72. 34 ± 4. 12 ) points], the differences were statistically significant (t =16.082,15.082,all P ＜0.05). Conclusion Treatment of advanced lung cancer with cinobufagin capsule combined with chemotherapy can significantly improve the coagulation state, treatment effect and quality of life of patients.